|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2012-09-27 |
/ Not yet recruiting临床2/3期IIT Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination With Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients With Newly Diagnosed Metastatic Ewing Sarcoma
This phase II/III trial compares the effect of vincristine, irinotecan, and regorafenib (VIrR) in combination with vincristine, doxorubicin, cyclophosphamide (VDC), ifosfamide and etoposide (IE) to usual treatment with VDC/IE for the treatment of newly diagnosed Ewing sarcoma or other round cell sarcomas that have spread from where they first started (primary site) to other places in the body (metastatic). Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair and may kill tumor cells. Regorafenib, a type of kinase inhibitor and a type of antiangiogenesis agent, blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells. It may also lower the body's immune response. Ifosfamide, a type of alkylating agent and a type of antimetabolite, attaches to DNA in cells and may kill tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Giving VIrR/VDC/IE may be more effective than usual treatment with VDC/IE in treating patients with newly diagnosed metastatic Ewing sarcoma or other round cell sarcomas.
100 项与 FGFR1 x TrkA x c-Kit x VEGFR1 x CSF-1R x PDGFRβ x VEGFR2 x DDR2 x Tie-2 x BRAF x CRAF x BRAF V600E x FRK x PDGFRα x RET x ABL x FGFR2 x VEGFR3 x EphA2 x MAPK11 相关的临床结果
100 项与 FGFR1 x TrkA x c-Kit x VEGFR1 x CSF-1R x PDGFRβ x VEGFR2 x DDR2 x Tie-2 x BRAF x CRAF x BRAF V600E x FRK x PDGFRα x RET x ABL x FGFR2 x VEGFR3 x EphA2 x MAPK11 相关的转化医学
0 项与 FGFR1 x TrkA x c-Kit x VEGFR1 x CSF-1R x PDGFRβ x VEGFR2 x DDR2 x Tie-2 x BRAF x CRAF x BRAF V600E x FRK x PDGFRα x RET x ABL x FGFR2 x VEGFR3 x EphA2 x MAPK11 相关的专利(医药)
亿帆医药股份有限公司(以下简称“亿帆医药”、“公司”)近日与拜耳医药保健有限公司(以下简称“拜耳”)就拜耳旗下经典靶向药拜万戈® (通用名:瑞戈非尼片)和多吉美®(通用名:甲苯磺酸索拉非尼片)签订商业化合作协议,协议约定,公司获得拜耳旗下经典靶向药拜万戈®和多吉美®在中国大陆地区的独家市场推广权益。
拜耳在消化系统肿瘤尤其是肝癌的治疗领域一直具有较强优势。其正式开启肝癌靶向治疗时代的代表产品多吉美®在独领风骚10年后,作为标准肝癌二线靶向治疗药物的拜万戈®在国内正式获批,再度重塑肝癌系统治疗全程管理新格局,并不断延长患者生存期。
拜万戈®适用于转移性结直肠癌、胃肠道间质瘤及肝细胞癌患者的治疗,多吉美®适用于晚期肾细胞癌、肝细胞癌及放射性碘难治性分化型甲状腺癌患者的治疗。两款产品已在全球100多个国家获得上市许可,在中国大陆,两款产品每年惠及数十万患者。根据国家癌症中心的报告,2022年中国新发癌症病例约482.47万,其中结直肠癌病例51.71万、甲状腺癌病例46.61万、肝癌病例36.77万、肾癌病例7.37万。
亿帆医药目前已拥有一支由300多人组成的专业、规范、成熟的肿瘤市场推广与销售团队,均拥有较强的肿瘤药品合规推广经验,且大部分拥有外资药企的肿瘤销售背景与经验。公司实体瘤团队主要负责希罗达®(卡培他滨片)、万赛维®(盐酸缬更昔洛韦片)、拜万戈®(瑞戈非尼片)、多吉美®(甲苯磺酸索拉非尼片)等产品的市场推广与销售,涉及结直肠癌、肝癌、胃癌、乳腺癌等治疗领域;血液肿瘤团队主要负责柏雪康®(复方黄黛片)、普帆乐®(普乐沙福注射液)、亿法拉®(氯法拉滨注射液)、爱克兰®(美法仑片)、硫酸长春新碱注射液、注射用阿柔比星等产品的市场推广与销售,涉及急性早幼粒细胞白血病、多发性骨髓瘤和恶性淋巴瘤及器官移植等治疗领域。
此次合作标志着公司在专业化推广和国际化合作迈上了新的台阶,为消化道肿瘤业务的发展引入了新的增长动力,是不断升级能力的重要里程碑。面向未来,公司肿瘤团队将继续坚持公司“创新、国际化”的发展战略,为社会创造价值,致力于打造成为国内一流的实体肿瘤与血液肿瘤领域市场推广与销售团队。
—— 声明
1.本资料目的在于提供疾病领域的相关知识、提高疾病认知水平,非广告用途。
2.本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或指导。